株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インターロイキン1受容体タイプ1:パイプライン製品の分析

Interleukin 1 Receptor Type 1 - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 520768
出版日 ページ情報 英文 54 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.68円で換算しております。
インターロイキン1受容体タイプ1:パイプライン製品の分析 Interleukin 1 Receptor Type 1 - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 54 Pages
概要

当レポートでは、インターロイキン1受容体タイプ1を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

インターロイキン1受容体タイプ1;概要

インターロイキン1受容体タイプ1;治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Paras Biopharmaceuticals Finland Oy
  • ProteoThera Inc
  • Swedish Orphan Biovitrum AB
  • XL-protein GmbH

薬剤プロファイル

休止中の製品

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Immune System Key Ltd, H2 2019
  • Pipeline by Onspira Therapeutics Inc, H2 2019
  • Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019
  • Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2019
  • Pipeline by ProteoThera Inc, H2 2019
  • Pipeline by Ribomic Inc, H2 2019
  • Pipeline by Swedish Orphan Biovitrum AB, H2 2019
  • Pipeline by XL-protein GmbH, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC2209TDB

Summary

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Interleukin 1 receptor, type I (IL1R1) or CD121a is an interleukin receptor encoded by IL1R1 gene. It plays an important role in many cytokine-induced immune and inflammatory responses. It mediates activation of NF-kappa-B, MAPK and other pathways.

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System, Gastrointestinal, Respiratory, Cardiovascular, Dermatology, Ear Nose Throat Disorders, Genetic Disorders and Musculoskeletal Disorders which include indications Inflammation, Rheumatoid Arthritis, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Inner Ear Disease (AIED), Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Crohn's Disease (Regional Enteritis), Gouty Arthritis (Gout), Inflammatory Bowel Disease, Intracerebral Hemorrhage, Limited/Distal Colitis, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ), Myelodysplastic Syndrome, Myocarditis, Osteoarthritis Pain, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma, Solid Tumor, Traumatic Brain Injury and Triple-Negative Breast Cancer (TNBC).

The latest report Interleukin 1 Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)
  • The report reviews Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Overview
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Companies Involved in Therapeutics Development
  • Immune System Key Ltd
  • Onspira Therapeutics Inc
  • Paradigm Biopharmaceuticals Ltd
  • Paras Biopharmaceuticals Finland Oy
  • ProteoThera Inc
  • Ribomic Inc
  • Swedish Orphan Biovitrum AB
  • XL-protein GmbH
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Drug Profiles
  • anakinra - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • anakinra biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Antagonize IL-1R1 for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IP-1510 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MBIL-1RA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nerofe - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OSP-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RBM-009 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XL-130 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Dormant Products
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Discontinued Products
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 03, 2018: Results from the anaGO study - a phase 2 study with anakinra in patients with acute gout
  • Sep 21, 2018: Phase2a Nerofe study has begun in Rabin and Kaplan medical centers
  • Sep 20, 2018: New way to target advanced breast cancers
  • Apr 11, 2018: Kineret (anakinra) approved in the EU for the treatment of Still's disease
  • Mar 26, 2018: Drug reduces inflammation in stroke patients
  • Feb 23, 2018: Kineret (anakinra) receives a positive opinion from CHMP for the treatment of Still's disease
  • Nov 21, 2017: Successful Completion of Phase I Nerofe Trial on Solid Tumor
  • Nov 16, 2017: First patient randomised in a phase 3 study evaluating safety and efficacy of anakinra in the treatment of Still's disease
  • May 30, 2017: Kineret approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease
  • Jan 11, 2017: First patient randomised in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout
  • Jun 06, 2016: Pfizer CentreOne to manufacture Sobi's Kineret drug substance
  • Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
  • Feb 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
  • Nov 01, 2015: Immune System Key: Nerofe's Triple Action
  • Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer